Amprenavir
Amprenavir is a pharmaceutical drug with 37 clinical trials. Historical success rate of 97.1%.
Success Metrics
Based on 33 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
15
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
94.3%
33 of 35 finished
5.7%
2 ended early
0
trials recruiting
37
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
Clinical Trials (37)
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir
A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients
Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers
A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV
Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients
Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance
Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
Once-Daily Drug Regimen for HIV-Infected Patients
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 37